Back to List
Effects on Productivity and Quality of Life of
Rizatriptan for Acute Migraine: A Workplace Study
Lainez MJA, Lopez A, Pascual AM.
Posted: December 2005
Objective: To evaluate the impact of
treatment with Rizatriptan 10 mg. on jobs and quality of life of
patients with migraine.
Methods: Prospective, open-label study at 27 work
sites of 20 companies representing diverse labor sectors in Spain.
Eligible patients according to International Headache Society
criteria were recruited for the study by on-site physicians and
instructed to treat moderate or severe migraine attacks with one
tablet of rizatriptan 10 mg. They were asked to complete the
study questionnaires at baseline, and then 3 months later.
Results: A total of 259 patients completed the
study. Only 7% had taken triptans before for treatment of their
migraine attacks. After 3 months of rizatriptan therapy, the use
of medical services was significantly lower and all tested domains
of quality of life had improved. Absenteeism and days worked during
migraine attacks also fell significantly during 3 months of
rizatriptan therapy as compared with the 3 months before the study.
The improvement in productivity was reflected in the significant
decreases in lost workday equivalents and also in the total number
of workdays lost. Two-thirds of patients described the efficacy of
oral rizatriptan as excellent or very good and 89% preferred it over
their usual medications for acute treatment of migraine attacks.
Conclusion: For this employed population of patients
with migraine, treatment with rizatriptan significantly improved
parameters measuring direct medical costs, work and productivity,
and health-related quality of life. In accordance with these
findings, direct and indirect costs related to migraine could be
substantially reduced by gathering detailed information about the
nature of headache, eliminating triggering factors, and instituting
effective treatment of migraine attacks.